Cathelicidins: A Novel Therapy for the Treatment of Intestinal Fibrosis?

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 1, 2015, Pages 2-3

  Vetrano, Stefania ^a   Genua, Marco ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CORTICOSTEROID; METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

CROHN DISEASE; DIAGNOSTIC ACCURACY; EDITORIAL; FIBROGENESIS; HUMAN; IMMUNOMODULATION; INTESTINAL FIBROSIS; INTESTINE OBSTRUCTION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMIC SCLEROSIS;

EID: 84928173515     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2014.12.001     Document Type: Editorial

References (3)

1. Denton C.P., Merkel P.A., Furst D.E., et al. Cat-192 Study G, Scleroderma Clinical Trials C. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:323-333.
2. Park H.J., Cho D.H., Kim H.J., et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. JInvest Dermatol 2009, 129:843-850.
3. Yoo J.H., Ho S., Tran D.H.-Y., et al. Antifibrogenic effects of the antimicrobial peptide cathelicidin in murine colitis-associated fibrosis. Cell Mol Gastroenterol Hepatol 2015, 1:55-74.